Similar articles for PMID: 34652430

Year	Number of Results
2010	1
2012	4
2013	4
2014	5
2015	9
2016	7
2017	5
2018	6
2019	23
2020	17
2021	24
2022	48
2023	12
2024	1

1

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancer.

Moriya T, Hamaji M, Yoshizawa A, Miyata R, Noguchi M, Tamari S, Chiba N, Miyamoto H, Toyazaki T, Tanaka S, Yamada Y, Yutaka Y, Nakajima D, Ohsumi A, Menju T, Date H. Moriya T, et al. Interact Cardiovasc Thorac Surg. 2022 Feb 21;34(3):416-423. doi: 10.1093/icvts/ivab283. Interact Cardiovasc Thorac Surg. 2022. PMID: 34652430 Free PMC article.

2

Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment for postoperative recurrent EGFR-mutated lung adenocarcinoma: a multi-institutional retrospective study.

Miyata R, Hamaji M, Kawaguchi A, Shimazu Y, Ikeda M, Ishikawa M, Kayawake H, Menju T, Kobayashi M, Okumura N, Sakaguchi Y, Sonobe M, Matsumoto A, Shoji T, Katakura H, Sumitomo R, Huang CL, Takahashi M, Aoyama A, Muranishi Y, Kono T, Miyahara R, Date N, Fujinaga T, Miyamoto E, Nakagawa T, Fukada T, Sakai H, Date H. Miyata R, et al. Eur J Cardiothorac Surg. 2022 Oct 4;62(5):ezac430. doi: 10.1093/ejcts/ezac430. Eur J Cardiothorac Surg. 2022. PMID: 35997576

3

[Survival analysis of different kinds of tyrosine kinase inhibitors in the treatment of patients with epidermal growth factor receptor mutated non-small cell lung cancer and leptomeningeal metastasis].

Xu HY, Chen HQ, Kong JX, Zhang Y, Liu S, Yang GJ, Wang Y. Xu HY, et al. Zhonghua Yi Xue Za Zhi. 2022 Feb 15;102(6):399-405. doi: 10.3760/cma.j.cn112137-20211009-02231. Zhonghua Yi Xue Za Zhi. 2022. PMID: 35144338 Chinese.

4

EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.

Tang W, Li X, Xie X, Sun X, Liu J, Zhang J, Wang C, Yu J, Xie P. Tang W, et al. Lung Cancer. 2019 Oct;136:6-14. doi: 10.1016/j.lungcan.2019.08.001. Epub 2019 Aug 2. Lung Cancer. 2019. PMID: 31421260

5

Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.

Chang LC, Lim CK, Chang LY, Chen KY, Shih JY, Yu CJ. Chang LC, et al. Eur J Cancer. 2019 Sep;119:77-86. doi: 10.1016/j.ejca.2019.06.025. Epub 2019 Aug 16. Eur J Cancer. 2019. PMID: 31425965

6

Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations.

Wang F, Diao XY, Zhang X, Shao Q, Feng YF, An X, Wang HY. Wang F, et al. Cancer Commun (Lond). 2019 Mar 2;39(1):7. doi: 10.1186/s40880-019-0354-z. Cancer Commun (Lond). 2019. PMID: 30823937 Free PMC article.

7

Distinct clinical outcomes of non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors: non-responders versus responders.

Hsiao SH, Liu HE, Lee HL, Lin CL, Chen WY, Wu ZH, Lin SE, Chiang LL, Chung CL. Hsiao SH, et al. PLoS One. 2013 Dec 23;8(12):e83266. doi: 10.1371/journal.pone.0083266. eCollection 2013. PLoS One. 2013. PMID: 24376677 Free PMC article.

8

Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.

Yu X, Sheng J, Pan G, Fan Y. Yu X, et al. Int J Cancer. 2021 Sep 1;149(5):1121-1128. doi: 10.1002/ijc.33677. Epub 2021 May 24. Int J Cancer. 2021. PMID: 33970485 Free article.

9

The efficacy of immune checkpoint inhibitors in advanced EGFR-Mutated non-small cell lung cancer after resistance to EGFR-TKIs: Real-World evidence from a multicenter retrospective study.

Hu J, Huang D, Wang Y, Li D, Yang X, Fu Y, Du N, Zhao Y, Li X, Ma J, Hu Y. Hu J, et al. Front Immunol. 2022 Sep 9;13:975246. doi: 10.3389/fimmu.2022.975246. eCollection 2022. Front Immunol. 2022. PMID: 36159795 Free PMC article.

10

Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.

Yan X, Wang H, Li P, Zhang G, Zhang M, Yang J, Zhang X, Zheng X, Ma Z. Yan X, et al. Lung Cancer. 2019 Feb;128:6-12. doi: 10.1016/j.lungcan.2018.12.007. Epub 2018 Dec 6. Lung Cancer. 2019. PMID: 30642455

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

144 results

Results by year